Incidence of CXCR4 tropism and CCR5-tropic resistance in treatment-experienced participants receiving maraviroc in the 48-week MOTIVATE 1 and 2 trials.

ABSTRACT:

SUBMITTER: Jubb B 

PROVIDER: S-EPMC6931239 | biostudies-literature | 2019 Jan-Dec

REPOSITORIES: biostudies-literature